Product Candidates
Acusphere's three product candidates, for which we have clinical data, are designed to address large unmet clinical needs in the areas of cardiology, oncology and asthma.
Imagify™(Perflubutane Polymer Microspheres) for Injectable Suspension, is a cardiovascular drug in development for the detection of coronary artery disease. A New Drug Application (NDA) for Imagify was submitted to FDA in April 2008.
AI-850™, completed U.S. Phase 1
A reformulation of the cancer drug paclitaxel and potential bio-equivalent to AbraxaneŽ. Licensed to Cephalon.
AI-128™, completed European Phase 1
An inhaled sustained release asthma formulation
>Click pipeline image for a larger view